Eli Lilly Shares Drop on Foundayo's Weak Performance; FDA Issues Psychedelic Vouchers
Eli Lilly's shares fell nearly 5% after weekly prescription numbers for its obesity drug Foundayo underperformed expectations, with sales projections revised downward. Meanwhile, the FDA announced it is issuing review vouchers to companies developing psychedelic treatments for mental health conditions.
Tickers: $AMGN $BBOT $LLY $NVO $REGN
Topics: Eli Lilly FDA Foundayo Prescription Data Psychedelics Stock Market